Sculptra Receives Approval For Smile Lines
Europeans have enjoyed the cosmetic advantages of Sculptra for almost a decade, but in the US, FDA approval has been limited to the correction of facial volume loss in HIV patients. But with its beauty benefits patently proven in American clinical trials, Sculptra has finally received the green light from the FDA to treat smile lines, or nasolabial folds, in healthy patients seeking an anti-aging effect.
Unlike other injectables that directly fill folds with hyaluronic acid or animal collagen for an instantly apparent difference, Sculptra (now being marketed as Sculptra Aesthetic) involves the injection of poly-L-lactic acid to stimulate the body's own collagen and gradually lift soft tissues in a way that lessens the look of lines.
Sculptra also differs from other fillers in that its effects can last as long as two years. One of the studies leading up to its approval showed that Sculptra-injected participants maintained results for up to 25 months, whereas participants receiving human-derived collagen injections saw the effects of their treatment wear off after three months.
Small lumps have been a side-effect concern with Sculptra, but most go away on their own. (Only one patient out of 233 in the clinical trials had to have a small lump surgically removed.)
Like all injectables, Sculptra should be administered by a medical professional, like a dermatologist or plastic surgeon, who has training and experience in injectables, so ask your chosen doctor about his or her history.
Find out more at the official Sculptra Aesthetic website.